Trial for new drug-resistant TB treatment to begin

March 19, 2012 by Jean-Louis Santini

A global health alliance Monday unveiled plans for the first clinical tests of a new treatment regimen for tuberculosis, including for patients with resistance to existing multidrug programs.

The TB Alliance, which is funded by several governments and foundations, said the new drug combination offers promise in the fight against TB, which kills an estimated 1.4 million people each year, mostly in Africa.

Health experts said the new program could be particularly useful for an estimated 650,000 people around the world who suffer from multidrug-resistant TB (MDR-TB), a number expected to rise, and could shorten treatment times.

"There is new momentum and new hope in TB research, as shown by this and several other novel regimen trials that will soon be launched," said Mel Spigelman, president and chief executive of the TB Alliance.

"This novel TB drug regimen has the potential to unlock a new and more efficient approach to tackling TB.

"In essence, it's a step toward erasing the distinction between TB and MDR-TB -- and in the process, dramatically shortening, simplifying, and improving treatment," he added.

Currently, someone with TB must take a course of drugs daily for six months, while those with MDR-TB must take a daily injection for the first six months and a dozen or more pills each day for 18 months or more.

Many TB patients fail to complete treatment because they cannot tolerate the difficult side effects of the medications or cannot adhere to the long-term treatment, according to the TB Alliance.

This leads to drug resistant forms of the disease, or even extensively drug-resistant TB known as XDR-TB.

"The current TB treatment takes too long, and all around the world, patients needlessly suffer because today's treatment is completely inadequate," said Francis George Apina of the Network of Men Living with HIV/AIDS in Kenya.

The TB Alliance receives funding from the Bill & Melinda Gates Foundation, Irish Aid, Britain's Department for International Development, the US Agency for International Development, and the US Food and Drug Administration.

The new regimen being tested could shorten required treatment to as little as four months in both patients with TB and some forms of drug-resistant TB, compared with the current six to 24 months. Costs will also be vastly reduced.

Once known as "consumption" for the slow wasting away of terminally-ill patients, one out of every three people is thought to be infected by the airborne TB organism, though only a fraction go on to develop the disease.

A total of 8.8 million people worldwide fell ill with the contagious lung disease in 2010 and around 1.4 million died, according to the World Health Organization (WHO).

The new trials will take place at eight sites in South Africa, Tanzania, and Brazil, the alliance said.

Dr Anthony Fauci, director of the US-based National Institute of Allergy and Infectious Diseases, said he was "optimistic" on the outlook for treating TB.

"We have put a lot of effort over the last few years in developing new drugs regimens and the clinical trial is a step in the right direction to trial and get new TB drugs, particularly for those against drugs resistance," he said.

"It's the first time we have tried to address the multi-resistance problem with a combination of new drugs. We tried before but not in combination," he added.

Explore further: Management of TB cases falls short of international standards

Related Stories

Management of TB cases falls short of international standards

February 9, 2012
The management of tuberculosis cases in the European Union (EU) is not meeting international standards, according to new research.

US urges shorter treatment for TB

December 8, 2011
US health authorities on Thursday urged a 12-week drug regimen for people with latent tuberculosis as an effective alternative to the current nine-month regimen which many people do not finish.

Recommended for you

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

'Superbugs' study reveals complex picture of E. coli bloodstream infections

July 18, 2017
The first large-scale genetic study of Escherichia coli (E. coli) cultured from patients with bloodstream infections in England showed that drug resistant 'superbugs' are not always out-competing other strains. Research by ...

Ebola virus can persist in monkeys that survived disease, even after symptoms disappear

July 17, 2017
Ebola virus infection can be detected in rhesus monkeys that survive the disease and no longer show symptoms, according to research published by Army scientists in today's online edition of the journal Nature Microbiology. ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.